[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prevention-of-influenza\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prevention-of-influenza":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100603229","phase-3-clinical-trial-to-evaluate-the-protective-efficacy-and-safety-of-a-nasal-spray-live-attenuated-influenza-vaccine-laiv-in-adults-aged-18-59-years-post-vaccination-100603229",false,"NCT07133802","Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination","A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine in Adults Aged 18-59 Years","Inclusion Criteria:\n\n1. Healthy participants aged 18-59 years\n2. Capable of providing informed consent in person\n3. Willing and able to comply with all clinical trial requirements\n\nExclusion Criteria:\n\n1. Axillary temperature \\>37.0°C on enrollment day \\*\n2. Received any influenza vaccine within the past 6 months or plans to receive other influenza vaccines during the trial\n3. History of laboratory-confirmed influenza (by clinical, serological, or microbiological methods) within the past 6 months\n4. Female participants of childbearing potential with positive urine pregnancy test, currently breastfeeding, or planning pregnancy within 6 months\n5. Acute phase of any infectious disease\u002Fchronic illness within 3 days, or recent use (≤3 days) of antipyretics\u002Fanalgesics\u002Fantihistamines \\*\n6. History of severe allergies requiring medical intervention (e.g., anaphylaxis, angioedema, Arthus reaction) or hypersensitivity to vaccine components (egg proteins, gentamicin sulfate, etc.)\n7. Known malignancies, autoimmune diseases (e.g., SLE, rheumatoid arthritis), or immunodeficiency (HIV, organ transplantation, etc.)\n8. Asplenia, functional asplenia, or any splenectomy history\n9. Use of immunosuppressants\u002Fimmunomodulators (e.g., systemic corticosteroids \\>14 days) within 6 months or planned use during study\n10. Congenital anomalies affecting organ function, uncontrolled hypertension (≥140\u002F90 mmHg despite treatment), or severe hepatic\u002Frenal diseases (e.g., diabetes-complicated)\n11. Active asthma or clinical remission for \\\u003C12 months\n12. History or family history of neurological\u002Fpsychiatric disorders (e.g., epilepsy, Guillain-Barré syndrome)\n13. Salicylate use (e.g., aspirin) within 30 days or planned use within 6 weeks post-vaccination\n14. Nasal abnormalities potentially affecting vaccine administration (e.g., active allergic rhinitis with medication, ongoing nasal sprays)\n15. Blood products\u002Fimmunoglobulin administration within 3 months or planned use during trial\n16. Live-attenuated vaccines within 14 days or subunit\u002Finactivated vaccines within 7 days prior to enrollment \\*\n17. Participation in other clinical trials within 1 month or concurrent involvement in interventional studies\n18. Any condition deemed by investigators to compromise trial integrity",true,"ALL","18 Years","59 Years",{"count":21,"type":22},6680,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination",[28],"Prevention of Influenza","NOT_YET_RECRUITING","2025-08-14",{"date":32,"type":33},"2025-08-21","ACTUAL",{"date":35,"type":22},"2025-08",{"date":37,"type":22},"2026-07",{"name":39,"class":40},"Changchun BCHT Biotechnology Co.","INDUSTRY"]